Georgeta - Camelia B.
- Country
- Romania
- Department
- Rheumatology
Research Overview
- A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
- Phase 3 Randomized Double-blind Placebo-controlled Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
- Phase 3 Randomized Double-Blind Study of Subcutaneous Sonelokimab in Biologic DMARD-Naive Adults with Active Psoriatic Arthritis
Data & Insights
Has run more than one trial at 165 of 300 partner sites.
Specializations
Rheumatology Focus
This investigator specializes in advancing treatments for psoriatic arthritis, particularly focusing on novel therapeutic approaches for patients with active disease manifestations.
- Autoimmune Conditions
- Joint Disease Management
- Inflammatory Arthritis
Their research encompasses evaluating innovative biological treatments for patients who have not previously received biologic disease-modifying antirheumatic drugs.
Therapeutic Innovation
The investigator's work centers on exploring subcutaneous therapeutic applications in rheumatologic conditions, with particular attention to novel biological agents.
- Biological Therapeutics
- Treatment Response Assessment
- Clinical Efficacy Evaluation
Their research involves investigating new treatment modalities for patients with active inflammatory joint conditions.
Clinical Assessment
The investigator specializes in evaluating treatment responses in rheumatologic conditions, particularly focusing on standardized assessment criteria.
- Disease Activity Monitoring
- Safety Assessment Protocols
- Treatment Optimization
Their expertise includes implementing systematic evaluation methods for assessing therapeutic outcomes in inflammatory joint conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.